cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.10011869
title: Supporting Data from Frustration and fidelity in influenza genome assembly

description: The Supporting Data file contains the following: SPLASH scores and co-localization indices for all 28 segment pairs (Sheet 1); `Stretched Bonds' scores and `RNA Contacts' scores for all trees (Sheet 2) and for the eight Pareto trees (sheet 3); tree probabilities under Gain/Loss and Gain-only evolution models (Sheet 4).
DOI: 10.14272/goisdoczkzyado-uhfffaoysa-n/chmo0000595
title: 13C nuclear magnetic resonance spectroscopy (13C NMR) (1-(4-phenylphenyl)ethanol)
title: InChI=1S/C14H14O/c1-11(15)12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-11,15H,1H3

description: dataset for 13C nuclear magnetic resonance spectroscopy (13C NMR) 13C NMR (100 MHz, DMSO-d6 [39.5 ppm], ppm) δ = 146.6 (1C, Cq), 140.2 (1C, Cq), 138.4 (1C, Cq), 128.9 (2C, CarH), 127.2 (1C, Car.H), 126.5 (2C, Car.H), 126.3 (2C, CarH), 125.9 (2C, CarH), 67.8 (1C, CHOH), 25.9 (1C, CH3).
DOI: 10.14272/goisdoczkzyado-uhfffaoysa-n/chmo0000470
title: mass spectrometry (MS) (1-(4-phenylphenyl)ethanol)
title: InChI=1S/C14H14O/c1-11(15)12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-11,15H,1H3

description: dataset for mass spectrometry (MS) EI (m/z, 70 eV, 40 °C): 198 (79) [M+], 183 (100) [M+ – CH3], 155 (96) [M+ – C2H5O + 2 H], 153 (27) [M+ – C2H5O + H], 152 (38) [M+ – C2H5O], 77 (27), 69 (24). HRMS–EI (m/z): [M]+ calcd for C14H14O, 198.1045; found, 198.1043.
DOI: 10.6084/m9.figshare.10011869.v1
title: Supporting Data from Frustration and fidelity in influenza genome assembly

description: The Supporting Data file contains the following: SPLASH scores and co-localization indices for all 28 segment pairs (Sheet 1); `Stretched Bonds' scores and `RNA Contacts' scores for all trees (Sheet 2) and for the eight Pareto trees (sheet 3); tree probabilities under Gain/Loss and Gain-only evolution models (Sheet 4).
DOI: 10.6084/m9.figshare.10011860
title: Metadata record for: Global map and indicators of food system sustainability

description: This dataset contains key characteristics about the data described in the Data Descriptor Global map and indicators of food system sustainability. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format 3. machine readable metadata file in ISA-Tab format (zipped folder)<br><br>Versioning Note:A revised version was generated when the metadata format was updated from JSON to JSON-LD. This was an automatic process that changed only the format, not the contents, of the metadata.
DOI: 10.14272/goisdoczkzyado-uhfffaoysa-n.1
title: 1-(4-phenylphenyl)ethanol
title: InChI=1S/C14H14O/c1-11(15)12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-11,15H,1H3

description: This dataset contains experimental data from a sample (1-(4-phenylphenyl)ethanol, InChI=1S/C14H14O/c1-11(15)12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-11,15H,1H3). The datasets from the following experiments are available: mass spectrometry (MS) infrared absorption spectroscopy (IR) 1H nuclear magnetic resonance spectroscopy (1H NMR) 13C nuclear magnetic resonance spectroscopy (13C NMR)
DOI: 10.14272/goisdoczkzyado-uhfffaoysa-n/chmo0000630
title: infrared absorption spectroscopy (IR) (1-(4-phenylphenyl)ethanol)
title: InChI=1S/C14H14O/c1-11(15)12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-11,15H,1H3

description: dataset for infrared absorption spectroscopy (IR) IR (ATR, ṽ) = 3301 (m), 3058 (w), 3030 (w), 2970 (w), 2927 (w), 2881 (w), 1483 (m), 1451 (w), 1402 (m), 1363 (w), 1289 (w), 1275 (w), 1193 (w), 1183 (w), 1167 (w), 1085 (s), 1069 (s), 1021 (w), 1004 (s), 894 (s), 834 (vs), 759 (vs), 727 (vs), 704 (m), 687 (vs), 637 (m), 605 (m), 562 (m), 506 (s), 428 (w), 411 (w), 392 (w), 381 (w) cm–1.
DOI: 10.6084/m9.figshare.10011860.v1
title: Metadata record for: Global map and indicators of food system sustainability

description: This dataset contains key characteristics about the data described in the Data Descriptor Global map and indicators of food system sustainability. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format 3. machine readable metadata file in ISA-Tab format (zipped folder)<br><br>Versioning Note:A revised version was generated when the metadata format was updated from JSON to JSON-LD. This was an automatic process that changed only the format, not the contents, of the metadata.
DOI: 10.6084/m9.figshare.10011770
title: Supplementary Material for: Psychiatric and Psychosomatic Consultation-Liaison Services in General Hospitals: A Systematic Review and Meta-Analysis of Effects on Symptoms of Depression and Anxiety

description: <b><i>Background:</i></b> Psychiatric and psychosomatic consultation-liaison services (CL) are important providers of diagnosis and treatment for hospital patients with mental comorbidities and psychological burdens. <b><i>Objective:</i></b> To perform a systematic review and meta-analysis investigating the effects of CL on depression and anxiety. <b><i>Methods:</i></b> Following PRISMA guidelines, a systematic literature search was conducted until 2017. Included were published randomized controlled trials using CL interventions with adults in general hospitals, treatment as usual as control groups, and depression and/or anxiety as outcomes. Risk of bias was assessed using the Cochrane Risk of Bias Tool. Level of integration was assessed using the Standard Framework for Levels of Integrated Healthcare. Meta-analyses were performed using random effects models and meta-regression for moderator effects. <b><i>Results:</i></b> We included 38 studies (9,994 patients). Risk of bias was high in 17, unclear in 15, and low in 6 studies. Studies were grouped by type of intervention: brief interventions tailored to the patients (8), interventions based on specific treatment manuals (19), and integrated, collaborative care (11). Studies showed small to medium effects on depression and anxiety. Meta-analyses for depression yielded a small effect (<i>d</i> = –0.19, 95% CI: –0.30 to –0.09) in manual studies and a small effect (<i>d</i> = –0.33, 95% CI: –0.53 to –0.13) in integrated, collaborative care studies, the latter using mostly active control groups with the possibility of traditional consultation. <b><i>Conclusions:</i></b> CL can provide a helpful first treatment for symptoms of depression and anxiety. Given that especially depressive symptoms in medically ill patients are long-lasting, the results underline the benefit of integrative approaches that respect the complexity of the illness.
DOI: 10.6084/m9.figshare.10011770.v1
title: Supplementary Material for: Psychiatric and Psychosomatic Consultation-Liaison Services in General Hospitals: A Systematic Review and Meta-Analysis of Effects on Symptoms of Depression and Anxiety

description: <b><i>Background:</i></b> Psychiatric and psychosomatic consultation-liaison services (CL) are important providers of diagnosis and treatment for hospital patients with mental comorbidities and psychological burdens. <b><i>Objective:</i></b> To perform a systematic review and meta-analysis investigating the effects of CL on depression and anxiety. <b><i>Methods:</i></b> Following PRISMA guidelines, a systematic literature search was conducted until 2017. Included were published randomized controlled trials using CL interventions with adults in general hospitals, treatment as usual as control groups, and depression and/or anxiety as outcomes. Risk of bias was assessed using the Cochrane Risk of Bias Tool. Level of integration was assessed using the Standard Framework for Levels of Integrated Healthcare. Meta-analyses were performed using random effects models and meta-regression for moderator effects. <b><i>Results:</i></b> We included 38 studies (9,994 patients). Risk of bias was high in 17, unclear in 15, and low in 6 studies. Studies were grouped by type of intervention: brief interventions tailored to the patients (8), interventions based on specific treatment manuals (19), and integrated, collaborative care (11). Studies showed small to medium effects on depression and anxiety. Meta-analyses for depression yielded a small effect (<i>d</i> = –0.19, 95% CI: –0.30 to –0.09) in manual studies and a small effect (<i>d</i> = –0.33, 95% CI: –0.53 to –0.13) in integrated, collaborative care studies, the latter using mostly active control groups with the possibility of traditional consultation. <b><i>Conclusions:</i></b> CL can provide a helpful first treatment for symptoms of depression and anxiety. Given that especially depressive symptoms in medically ill patients are long-lasting, the results underline the benefit of integrative approaches that respect the complexity of the illness.
DOI: 10.6084/m9.figshare.10011788.v1
title: State of Open Data 2019

description: Raw data and questionnaire from the Springer Nature - Digital Science collaboration of an annual survey of research authors on their attitudes and behaviour around research data.
DOI: 10.6084/m9.figshare.10011695
title: Untitled Item

description: Reduction of C. jejuni in chickens and quorum sensing inhibition with a-pinene. Resistance modulation in vitro.
DOI: 10.6084/m9.figshare.10011695.v1
title: Untitled Item

description: Reduction of C. jejuni in chickens and quorum sensing inhibition with a-pinene. Resistance modulation in vitro.
DOI: 10.6084/m9.figshare.10011671
title: Supplementary Material for: A Self-Reported Version of the Measurements in the Addictions for Triage and Evaluation-Q: Concurrent Validity with the MATE 2.1

description: <b><i>Introduction:</i></b> Substance abuse treatment centers require reliable and valid instruments to monitor treatment progress, to evaluate treatment effectiveness, and to initiate clinical trials. Currently the Measurements in the Addictions for Triage and Evaluation (MATE) 2.1, an instrument that serves these purposes, is considered quite lengthy and intensive, especially in the case of allocation to milder treatment intensity. Therefore, a self-reported version of the MATE-Q was designed for patients with mild to moderate substance-abuse and co-occurring problems. The aim of the present study was to assess concurrent validity with the interviewer version of the MATE (version 2.1). <b><i>Materials and Methods:</i></b> Data were collected at 2 locations of a Dutch substance abuse treatment center, one location in a large city and one in a suburban area. A correlational design was employed, where each included participant completed a MATE-Q and a MATE 2.1 within 3 days or less (administered at intake, before treatment initiation). A total of 98 treatment-seeking patients were included (51.0% alcohol as a primary problem, 19.4% cannabis, 14.3% gambling and 6.1% cocaine). Measurements included the MATE-Q and the MATE 2.1. Intraclass correlation coefficients (ICCs) for single measures were calculated, deploying the 2-way mixed procedure with absolute agreement. Descriptives of scores comprise means and Cronbach’s alpha for internal consistency. <b><i>Results:</i></b> For the majority (15 out of 24) of the scores ICCs were equal or above 0.7. For 93 patients (95%), the primary problem substance or problem behavior was reported correspondingly. Nine MATE-Q mean scores differed significantly from their MATE 2.1 counterparts. <b><i>Discussion/Conclusion:</i></b> For the majority of scores, the MATE-Q has acceptable concurrent validity for the assessment of patients with mild to moderate substance abuse and co-occurring problems.
DOI: 10.6084/m9.figshare.10011671.v1
title: Supplementary Material for: A Self-Reported Version of the Measurements in the Addictions for Triage and Evaluation-Q: Concurrent Validity with the MATE 2.1

description: <b><i>Introduction:</i></b> Substance abuse treatment centers require reliable and valid instruments to monitor treatment progress, to evaluate treatment effectiveness, and to initiate clinical trials. Currently the Measurements in the Addictions for Triage and Evaluation (MATE) 2.1, an instrument that serves these purposes, is considered quite lengthy and intensive, especially in the case of allocation to milder treatment intensity. Therefore, a self-reported version of the MATE-Q was designed for patients with mild to moderate substance-abuse and co-occurring problems. The aim of the present study was to assess concurrent validity with the interviewer version of the MATE (version 2.1). <b><i>Materials and Methods:</i></b> Data were collected at 2 locations of a Dutch substance abuse treatment center, one location in a large city and one in a suburban area. A correlational design was employed, where each included participant completed a MATE-Q and a MATE 2.1 within 3 days or less (administered at intake, before treatment initiation). A total of 98 treatment-seeking patients were included (51.0% alcohol as a primary problem, 19.4% cannabis, 14.3% gambling and 6.1% cocaine). Measurements included the MATE-Q and the MATE 2.1. Intraclass correlation coefficients (ICCs) for single measures were calculated, deploying the 2-way mixed procedure with absolute agreement. Descriptives of scores comprise means and Cronbach’s alpha for internal consistency. <b><i>Results:</i></b> For the majority (15 out of 24) of the scores ICCs were equal or above 0.7. For 93 patients (95%), the primary problem substance or problem behavior was reported correspondingly. Nine MATE-Q mean scores differed significantly from their MATE 2.1 counterparts. <b><i>Discussion/Conclusion:</i></b> For the majority of scores, the MATE-Q has acceptable concurrent validity for the assessment of patients with mild to moderate substance abuse and co-occurring problems.
DOI: 10.6084/m9.figshare.10011659
title: Supplementary Material for: Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis

description: <b><i>Objectives:</i></b> This study aimed to assess the real-world rates of treatment discontinuation and switching of biologic therapies in patients with inflammatory bowel disease (IBD). <b><i>Methods:</i></b> A retrospective claims data analysis on all continuously insured adult IBD patients with initiation of a biologic therapy was conducted. Observation started with the date of the first prescription of index tumor necrosis factor α-inhibitors (anti-TNFα) or vedolizumab (VDZ) therapy and lasted 12 months. Non-persistence was assumed in case of a switch to another biologic or a treatment gap of &gt;90 days. <b><i>Results:</i></b> We included 1,248 IBD biologic treatment starters (502 adalimumab, 77 golimumab, 441 infliximab, 228 VDZ); 837/411 were biologic-naïve (bio-naïve)/ biologic-experienced (bio-experienced). Mean age of bio-naïve/bio-experienced anti-TNFα patients was 39.2/38.1 years (54.9%/56.7% female) and 42.6/37.8 years for VDZ patients (56.3%/54.9% female). Seven hundred and seventy-two patients (61.9%) were persistent with their index biologic therapy after 12 months (61.9%/61.8% bio-naïve/bio-experienced). Percentage of persistent patients was 69.7% for VDZ (65.6%/71.3%) and 60.1% for anti-TNFα (61.4%/55.5%). VDZ was associated with later non-persistence in a multivariable Cox regression analysis (hazard ratio 0.675; <i>p</i> = 0.003) compared to anti-TNFα. <b><i>Conclusions:</i></b> Only 60–70% of IBD ­patients are still persistent with their biologic therapy after 12 months. VDZ therapy is associated with a higher persistence than anti-TNFα therapy in this analysis.
DOI: 10.6084/m9.figshare.10011563
title: Supplementary Material for: A Novel Polymorphism (rs35612982) in <b><i>CDKAL1</i></b> Is a Risk Factor of Type 2 Diabetes: A Case-Control Study

description: <b><i>Background:</i></b> The interaction of environmental factors and genetic factors may contribute to the risk of type 2 diabetes (T2D). We aimed to investigate whether age, gender, body mass index (BMI) and lifestyle factors have an effect on the association between the <i>CDKAL1</i> polymorphisms and T2D. <b><i>Methods:</i></b> Eight single nucleotide polymorphisms in <i>CDKAL1</i> were genotyped by Agena MassARRAY in 508 T2D patients and 503 controls. The association between the <i>CDKAL1</i> polymorphisms and T2D was evaluated using logistic regression model by calculating OR and 95% CIs. <b><i>Results:</i></b> We found a significant association between <i>CDKAL1</i> polymorphisms (rs4712523, OR 1.42, <i>p</i> = 9.44 × 10<sup>–5</sup>; rs4712524, OR 1.38, <i>p</i> = 3.28 × 10<sup>–4</sup>; rs10946398, OR 1.43, <i>p</i> = 6.21 × 10<sup>–5</sup>; rs7754840, OR 1.43, <i>p</i> = 6.33 × 10<sup>–5</sup>; rs35612982, OR 1.34, <i>p</i> = 0.0010; and rs10440833, OR 1.32, <i>p</i> = 0.0018) and T2D risk among the Han population from Northwest China. We also found that genetic variants of <i>CDKAL1</i> could modify the risk of T2D that might be influenced by age, BMI and the status of smoking and drinking. Besides, rs35612982-CT (<i>p</i> = 0.038) and rs10440833-AT (<i>p</i> = 0.044) genotypes were higher insulin level. <b><i>Conclusion:</i></b><i> CDKAL1</i> rs35612982 (C/T) polymorphism, as a new polymorphism, was associated with the increased risk of T2D in the Han Chinese population. Moreover, the contribution of<i> CDKAL1</i> polymorphisms to T2D risk seems to be associated with age, gender, BMI, smoking and drinking.
DOI: 10.6084/m9.figshare.10011563.v1
title: Supplementary Material for: A Novel Polymorphism (rs35612982) in <b><i>CDKAL1</i></b> Is a Risk Factor of Type 2 Diabetes: A Case-Control Study

description: <b><i>Background:</i></b> The interaction of environmental factors and genetic factors may contribute to the risk of type 2 diabetes (T2D). We aimed to investigate whether age, gender, body mass index (BMI) and lifestyle factors have an effect on the association between the <i>CDKAL1</i> polymorphisms and T2D. <b><i>Methods:</i></b> Eight single nucleotide polymorphisms in <i>CDKAL1</i> were genotyped by Agena MassARRAY in 508 T2D patients and 503 controls. The association between the <i>CDKAL1</i> polymorphisms and T2D was evaluated using logistic regression model by calculating OR and 95% CIs. <b><i>Results:</i></b> We found a significant association between <i>CDKAL1</i> polymorphisms (rs4712523, OR 1.42, <i>p</i> = 9.44 × 10<sup>–5</sup>; rs4712524, OR 1.38, <i>p</i> = 3.28 × 10<sup>–4</sup>; rs10946398, OR 1.43, <i>p</i> = 6.21 × 10<sup>–5</sup>; rs7754840, OR 1.43, <i>p</i> = 6.33 × 10<sup>–5</sup>; rs35612982, OR 1.34, <i>p</i> = 0.0010; and rs10440833, OR 1.32, <i>p</i> = 0.0018) and T2D risk among the Han population from Northwest China. We also found that genetic variants of <i>CDKAL1</i> could modify the risk of T2D that might be influenced by age, BMI and the status of smoking and drinking. Besides, rs35612982-CT (<i>p</i> = 0.038) and rs10440833-AT (<i>p</i> = 0.044) genotypes were higher insulin level. <b><i>Conclusion:</i></b><i> CDKAL1</i> rs35612982 (C/T) polymorphism, as a new polymorphism, was associated with the increased risk of T2D in the Han Chinese population. Moreover, the contribution of<i> CDKAL1</i> polymorphisms to T2D risk seems to be associated with age, gender, BMI, smoking and drinking.
DOI: 10.6084/m9.figshare.10011482
title: Supplementary Material for: Intraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer

description: <b><i>Objectives:</i></b> This study aimed to determine the effect of intraoperative administration of flurbiprofen on postoperative levels of programmed death 1 (PD-1) in patients undergoing thoracoscopic surgery. <b><i>Materials and Methods:</i></b> In this prospective double-blind trial, patients were randomized to receive intralipid (control group, <i>n</i> = 34, 0.1 mL/kg, i.v.) or flurbiprofen axetil (flurbiprofen group, <i>n</i> = 34, 50 mg, i.v.) before induction of anesthesia. PD-1 levels on T cell subsets, inflammation, and immune markers in peripheral blood were examined before the induction of anesthesia (T<sub>0</sub>) and 24 h (T<sub>1</sub>), 72 h (T<sub>2</sub>), and 1 week (T<sub>3</sub>) after surgery. A linear mixed model was used to determine whether the changes from baseline values (T<sub>0</sub>) between groups were significantly different. <b><i>Results:</i></b> The increases in the percentage of PD-1<sup>(+)</sup>CD8<sup>(+)</sup> T cells observed at T<sub>1</sub> and T<sub>2</sub> in the control group were higher than those in the flurbiprofen group (T<sub>1</sub>: 12.91 ± 1.65 vs. 7.86 ± 5.71%, <i>p</i> = 0.031; T<sub>2</sub>: 11.54 ± 1.54 vs. 8.75 ± 1.73%, <i>p</i> = 0.004), whereas no differences were observed in the changes in the percentage of PD-1<sup>(+)</sup>CD4<sup>(+)</sup> T cells at T<sub>1</sub> and T<sub>2</sub> between the groups. Moreover, extensive changes in the percentage of lymphocyte subsets and inflammatory marker concentrations were observed at T<sub>1</sub> and T<sub>2</sub> after surgery and flurbiprofen attenuated most of these changes. <b><i>Conclusions:</i></b> Perioperative administration of flurbiprofen attenuated the postoperative increase in PD-1 levels on CD8<sup>(+)</sup> T cells up to 72 h after surgery, but not after this duration. The clinical relevance of changes in PD-1 levels to long-term surgical outcome remains unknown.
DOI: 10.6084/m9.figshare.10011467
title: Supplementary Material for: Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients

description: <b><i>Introduction:</i></b> Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is considered a safe and minimally invasive procedure. We previously reported that the mortality and complication rates for RFA were 0.038% (5/13,283 patients) and 3.54% (579 complications/16,346 procedures), respectively, from 1999 to 2010 (previous period). In this study, we investigated the clinical criteria for RFA and the mortality and complication rates from 2011 to 2015 (recent period). <b><i>Methods:</i></b> Data were collected from 25 centers by using a questionnaire developed by the Chugoku-Shikoku Society for Local Ablation Therapy of HCC. The criteria for RFA, RFA modification, use of image-guidance modalities, mortality, and complications during the previous and recent periods were compared. <b><i>Results:</i></b> We evaluated 11,298 procedures for 9,411 patients, including those that involved new devices (bipolar RFA and internally adjustable electrode system). The criterion of hepatic function for RFA increased from a Child-Pugh score ≤8 during the previous period to ≤9 during the recent period. The criteria regarding the tumor location and other risk factors have been expanded recently because of the increased use of several modifications of the RFA procedure and image-guidance modalities. The mortality rate was 0.064% (6/9,411 patients), and the complication rate was 2.92% (330 complications/11,298 procedures). There was no difference in mortality rates between the 2 periods (<i>p</i> = 0.38), but the complication rates was significantly lower during the recent period (<i>p</i> = 0.038). <b><i>Discussion and Conclusions:</i></b> Our findings confirmed that RFA, including the use of new devices, is a low-risk procedure for HCC, despite the expansion of the criteria for RFA during the recent period.
DOI: 10.6084/m9.figshare.10011434
title: grid.420067.7

description: Network data for What does NZ research look like<br>
DOI: 10.6084/m9.figshare.10011428
title: overleaf_mapping

description: Control file for mapping files to overleaf project<br>
DOI: 10.6084/m9.figshare.10011434.v1
title: grid.420067.7

description: Network data for What does NZ research look like<br>